PGT - PREIMPLANTATION GENETIC TESTING

Under development pending review and approval of tests by  NHRA ( National Health regulatory Authority)

Preimplantation Genetic Testing (PGT) is a test used to detect genetic abnormalities in embryos before transferring the healthy unaffected ones into the mother.

For example, if both parents were carriers of the autosomal recessive condition “Sickle Cell Disease”, there will always be a 25% chance of the baby being affected. To avoid this risk, after IVF, the embryo is biopsied on the 3rd day after fertilization. One cell from each embryo will be analyzed to know which embryo is affected, carrier or unaffected (healthy). The healthy unaffected embryo will then be recommended for transfer.

In many cases and because the carriers of the autosomal recessive conditions do not show any signs of the disease, many do not know that they are carriers and therefore do not know the risk of transferring this condition to their offspring until they have an affected child. In such cases the Genetic Screening Test is highly recommended especially for consanguineous marriages. Such individuals would benefit from PGT to avoid having children born with that genetic condition.

Preimplantation Genetic Testing (PGT) refers to the three types of tests that maybe preformed on embryos during IVF 

PGT-A (Preimplantation Genetic Testing for Aneuploidies for abnormal chromosome number)
PGT-M (Preimplantation Genetic Testing for Monogenic/ Single Gene Defects)
​PGT-SR (Preimplantation Genetic Testing for Chromosomal Structural Rearrangements for chromosomal mis-arrangements such as inversion and translocations)

For more information, please contact 17237303